Want to see IL:NVLG full AI Analyst Report?
Novolog (NVLG) AI Stock Analysis
Novolog
(TASE:NVLG)
The overall score reflects a solid but risk-exposed financial profile, where a sizeable revenue base and acceptable leverage are outweighed by margin compression, negative recent returns on equity, and volatile cash generation. Secondary support comes from constructive short-term technical momentum within a weaker long-term trend, and a valuation mix of a high-risk negative P/E alongside a comparatively attractive dividend yield.
Novolog (NVLG) vs. iShares MSCI Israel ETF (EIS)
- Market Cap
- ILS 434.75M
- Dividend Yield
- 4.60%
- Average Volume (3M)
- 601.74K
- Price to Earnings (P/E)
- -643.8
- Beta (1Y)
- 0.75
- Revenue Growth
- -13.76%
- EPS Growth
- -103.31%
- Country
- Israel
- Employees
- 916
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Distribution
Novolog Business Overview & Revenue Model
Company Description
Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Healthcare Services, and Digital. The Logistics division engages in the import and distribution of pharmaceuticals and medica...
Novolog Financial Statement Overview
Summary
Revenue has grown to a sizeable scale, but recent margin compression, unstable profitability, and volatile cash flows weaken financial resilience despite a moderately leveraged, generally supportive balance sheet.
Income Statement
52NeutralBalance Sheet
65PositiveCash Flow
48Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.81B | 1.81B | 2.02B | 1.64B | 1.51B | 1.26B |
| Gross Profit | 137.75M | 124.09M | 180.78M | 173.76M | 176.15M | 148.96M |
| EBITDA | 105.05M | 100.75M | 149.39M | 130.14M | 138.53M | 115.92M |
| Net Income | -674.00K | 4.12M | 39.54M | -42.00M | 47.51M | 42.32M |
Balance Sheet | ||||||
| Total Assets | 2.71B | 2.15B | 3.04B | 2.79B | 2.43B | 2.29B |
| Cash, Cash Equivalents and Short-Term Investments | 204.46M | 121.77M | 247.60M | 232.94M | 172.81M | 238.71M |
| Total Debt | 171.19M | 183.20M | 198.47M | 215.18M | 212.77M | 166.81M |
| Total Liabilities | 2.35B | 1.78B | 2.65B | 2.39B | 1.97B | 1.86B |
| Stockholders Equity | 350.91M | 356.85M | 368.38M | 371.08M | 436.00M | 424.37M |
Cash Flow | ||||||
| Free Cash Flow | 71.82M | -34.22M | 99.78M | 129.06M | 63.16M | 52.75M |
| Operating Cash Flow | 70.18M | -16.50M | 158.52M | 200.01M | 132.65M | 83.39M |
| Investing Cash Flow | -40.34M | -61.92M | -50.55M | -72.60M | -124.95M | -69.07M |
| Financing Cash Flow | -48.86M | -46.02M | -94.59M | -67.71M | -72.96M | 47.49M |
Novolog Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NVLG, the sentiment is Positive. The current price of 85.10 is above the 20-day moving average (MA) of 84.34, above the 50-day MA of 80.42, and below the 200-day MA of 93.74, indicating a neutral trend. The MACD of 1.32 indicates Positive momentum. The RSI at 53.99 is Neutral, neither overbought nor oversold. The STOCH value of 26.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:NVLG.
Novolog Peers Comparison
Overall Rating
- IL:NVLG55Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IL:NVLG | 55Neutral | ILS 430.16M | -643.85 | ― | 4.60% | -13.76% | -103.31% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IL:NVLG | Novolog (Pharm UP 1966) Ltd. | 85.10 | -41.26 | -32.65% | |
| IL:BONS | Bonus Biogroup | 17.60 | -3.80 | -17.76% | |
| IL:ILX | ILEX Medical Ltd. | 4827.00 | -1556.05 | -24.38% | |
| IL:GEFR | Cannomed Medical Cannabis Industries Ltd. | 77.40 | -4.00 | -4.91% | |
| IL:MDPR | Medipower (Overseas) Public Co. Limited. | 477.50 | -221.23 | -31.66% | |
| IL:EPIT | EPITOMEE MEDICAL LTD | 348.50 | -425.80 | -54.99% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 08, 2026